VivoSeq
Oncology

Myeloid Neoplasm

36

Pipeline Programs↗

6

Active Trials↗

21

Companies Involved↗

Myeloid Neoplasm is a moderately active landscape with 36 programs across 21 companies. The most active players are Incyte, AbbVie, Sun Pharma. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

0/100

Mech. Concentration

12/100

Completion Rate

90/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

2 programs

Phase 1AbbVie logo

AbbVie

2 programs

Phase 1Sun Pharma logo

Sun Pharma

1 program

Phase 1S

Servier

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

2 programs

Phase 2Teva logo

Teva

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

32 of 37 classified programs — the dominant modality here.

14%ALL OTHERSProtein / enzyme25%Cell therapy25%Antibody–drug conjugate13%

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 39 pipeline programs.

Analysis

Trial Status

16

clinical trials

Completed9 · 56%
Active, not recruiting4 · 25%
Recruiting1 · 6%
Not yet recruiting1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

16 trials

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Recruiting·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 2/3·NCT04256317·316 enrolled
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Active, not recruiting·Incyte logoIncyte·Phase 1·NCT04279847·140 enrolled
Inqovi Maintenance Therapy in Myeloid Neoplasms
Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT04980404·22 enrolled
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Active, not recruiting·JJacqueline Garcia, MD·Phase 1·NCT05455294·16 enrolled
A Prospective, Single Site, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT05656248·25 enrolled
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06900088·20 enrolled
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Completed·UUniversity of Washington·Phase 2·NCT02756572·30 enrolled
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
Completed·HHeinrich-Heine University, Duesseldorf·Phase 2·NCT04522895·50 enrolled
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Completed·MMassachusetts General Hospital·Phase 1·NCT03564821·18 enrolled
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Completed·HHospital Israelita Albert Einstein·Phase 2·NCT02084563·455 enrolled
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Completed·MMassachusetts General Hospital·Phase 1·NCT03515512·23 enrolled
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Completed·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT00665002·16 enrolled
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
Completed·—·Phase 3·NCT01387763·202 enrolled
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03072043·55 enrolled
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT03531918·66 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)